Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995576977> ?p ?o ?g. }
- W2995576977 endingPage "340" @default.
- W2995576977 startingPage "330" @default.
- W2995576977 abstract "Treatment of ventilated pneumonia is often unsuccessful, even when patients are treated according to established guidelines. Therefore, we aimed to investigate the efficacy of the combination drug device Amikacin Inhale as an adjunctive therapy to intravenous standard-of-care antibiotics for pneumonia caused by Gram-negative pathogens in intubated and mechanically ventilated patients.INHALE was a prospective, double-blind, randomised, placebo-controlled, phase 3 study comprising two trials (INHALE 1 and INHALE 2) done in 153 hospital intensive-care units in 25 countries. Eligible patients were aged 18 years or older; had pneumonia that had been diagnosed by chest radiography and that was documented as being caused by or showing two risk factors for a Gram-negative, multidrug-resistant pathogen; were intubated and mechanically ventilated; had impaired oxygenation within 48 h before screening; and had a modified Clinical Pulmonary Infection Score of at least 6. Patients were stratified by region and disease severity (according to their Acute Physiology and Chronic Health Evaluation [APACHE] II score) and randomly assigned (1:1) via an interactive voice-recognition system to receive 400 mg amikacin (Amikacin Inhale) or saline placebo, both of which were aerosolised, administered every 12 h for 10 days via the same synchronised inhalation system, and given alongside standard-of-care intravenous antibiotics. All patients and all staff involved in administering devices and monitoring outcomes were masked to treatment assignment. The primary endpoint, survival at days 28-32, was analysed in all patients who received at least one dose of study drug, were infected with a Gram-negative pathogen, and had an APACHE II score of at least 10 at diagnosis. Safety analyses were done in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, numbers NCT01799993 and NCT00805168.Between April 13, 2013, and April 7, 2017, 807 patients were assessed for eligibility and 725 were randomly assigned to Amikacin Inhale (362 patients) or aerosolised placebo (363 patients). 712 patients received at least one dose of study drug (354 in the Amikacin Inhale group and 358 in the placebo group), although one patient assigned to Amikacin Inhale received placebo in error and was included in the placebo group for safety analyses. 508 patients (255 in the Amikacin Inhale group and 253 in the placebo group) were assessed for the primary endpoint. We found no between-group difference in survival: 191 (75%) patients in the Amikacin Inhale group versus 196 (77%) patients in the placebo group survived until days 28-32 (odds ratio 0·841, 95% CI 0·554-1·277; p=0·43). Similar proportions of patients in the two treatment groups had a treatment-emergent adverse event (295 [84%] of 353 patients in the Amikacin Inhale group vs 303 [84%] of 359 patients in the placebo group) or a serious treatment-emergent adverse event (101 [29%] patients vs 97 [27%] patients).Our findings do not support use of inhaled amikacin adjunctive to standard-of-care intravenous therapy in mechanically ventilated patients with Gram-negative pneumonia.Bayer AG." @default.
- W2995576977 created "2019-12-26" @default.
- W2995576977 creator A5006829545 @default.
- W2995576977 creator A5013038112 @default.
- W2995576977 creator A5013718821 @default.
- W2995576977 creator A5021758461 @default.
- W2995576977 creator A5022407641 @default.
- W2995576977 creator A5039694085 @default.
- W2995576977 creator A5040669754 @default.
- W2995576977 creator A5049362550 @default.
- W2995576977 creator A5057252015 @default.
- W2995576977 creator A5063403222 @default.
- W2995576977 creator A5073518693 @default.
- W2995576977 creator A5074593854 @default.
- W2995576977 creator A5084811801 @default.
- W2995576977 creator A5090740872 @default.
- W2995576977 creator A5091280671 @default.
- W2995576977 date "2020-03-01" @default.
- W2995576977 modified "2023-10-16" @default.
- W2995576977 title "Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial" @default.
- W2995576977 cites W1892779545 @default.
- W2995576977 cites W1979999578 @default.
- W2995576977 cites W1986588705 @default.
- W2995576977 cites W2049676110 @default.
- W2995576977 cites W2089928475 @default.
- W2995576977 cites W2095656393 @default.
- W2995576977 cites W2100154890 @default.
- W2995576977 cites W2103616926 @default.
- W2995576977 cites W2103780797 @default.
- W2995576977 cites W2114034330 @default.
- W2995576977 cites W2115281408 @default.
- W2995576977 cites W2118677651 @default.
- W2995576977 cites W2123793178 @default.
- W2995576977 cites W2131271565 @default.
- W2995576977 cites W2133979383 @default.
- W2995576977 cites W2134359209 @default.
- W2995576977 cites W2144973926 @default.
- W2995576977 cites W2150498285 @default.
- W2995576977 cites W2153641174 @default.
- W2995576977 cites W2171704992 @default.
- W2995576977 cites W2293606698 @default.
- W2995576977 cites W2340263817 @default.
- W2995576977 cites W2372593737 @default.
- W2995576977 cites W2473016454 @default.
- W2995576977 cites W2554651062 @default.
- W2995576977 cites W2594024824 @default.
- W2995576977 cites W2741076572 @default.
- W2995576977 cites W2752537900 @default.
- W2995576977 cites W4211194064 @default.
- W2995576977 doi "https://doi.org/10.1016/s1473-3099(19)30574-2" @default.
- W2995576977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31866328" @default.
- W2995576977 hasPublicationYear "2020" @default.
- W2995576977 type Work @default.
- W2995576977 sameAs 2995576977 @default.
- W2995576977 citedByCount "70" @default.
- W2995576977 countsByYear W29955769772020 @default.
- W2995576977 countsByYear W29955769772021 @default.
- W2995576977 countsByYear W29955769772022 @default.
- W2995576977 countsByYear W29955769772023 @default.
- W2995576977 crossrefType "journal-article" @default.
- W2995576977 hasAuthorship W2995576977A5006829545 @default.
- W2995576977 hasAuthorship W2995576977A5013038112 @default.
- W2995576977 hasAuthorship W2995576977A5013718821 @default.
- W2995576977 hasAuthorship W2995576977A5021758461 @default.
- W2995576977 hasAuthorship W2995576977A5022407641 @default.
- W2995576977 hasAuthorship W2995576977A5039694085 @default.
- W2995576977 hasAuthorship W2995576977A5040669754 @default.
- W2995576977 hasAuthorship W2995576977A5049362550 @default.
- W2995576977 hasAuthorship W2995576977A5057252015 @default.
- W2995576977 hasAuthorship W2995576977A5063403222 @default.
- W2995576977 hasAuthorship W2995576977A5073518693 @default.
- W2995576977 hasAuthorship W2995576977A5074593854 @default.
- W2995576977 hasAuthorship W2995576977A5084811801 @default.
- W2995576977 hasAuthorship W2995576977A5090740872 @default.
- W2995576977 hasAuthorship W2995576977A5091280671 @default.
- W2995576977 hasConcept C126322002 @default.
- W2995576977 hasConcept C142724271 @default.
- W2995576977 hasConcept C177713679 @default.
- W2995576977 hasConcept C203092338 @default.
- W2995576977 hasConcept C204787440 @default.
- W2995576977 hasConcept C27081682 @default.
- W2995576977 hasConcept C2777427914 @default.
- W2995576977 hasConcept C2777914695 @default.
- W2995576977 hasConcept C2987404301 @default.
- W2995576977 hasConcept C3018162438 @default.
- W2995576977 hasConcept C42219234 @default.
- W2995576977 hasConcept C501593827 @default.
- W2995576977 hasConcept C535046627 @default.
- W2995576977 hasConcept C71924100 @default.
- W2995576977 hasConcept C86803240 @default.
- W2995576977 hasConcept C89423630 @default.
- W2995576977 hasConceptScore W2995576977C126322002 @default.
- W2995576977 hasConceptScore W2995576977C142724271 @default.
- W2995576977 hasConceptScore W2995576977C177713679 @default.
- W2995576977 hasConceptScore W2995576977C203092338 @default.
- W2995576977 hasConceptScore W2995576977C204787440 @default.
- W2995576977 hasConceptScore W2995576977C27081682 @default.
- W2995576977 hasConceptScore W2995576977C2777427914 @default.